• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 5. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Introduction to 4-Bromo-1-methyl-1H-indazole (CAS No. 365427-30-1)

4-Bromo-1-methyl-1H-indazole, identified by the Chemical Abstracts Service Number (CAS No.) 365427-30-1, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical and chemical research. This compound belongs to the indazole family, characterized by a fused benzene and pyrrole ring system, with a bromine substituent at the 4-position and a methyl group at the 1-position. The unique structural features of 4-Bromo-1-methyl-1H-indazole make it a versatile intermediate in synthetic chemistry and a promising candidate for further exploration in drug discovery.

The indazole scaffold is well-documented for its biological activity, with numerous derivatives exhibiting pharmacological properties ranging from antimicrobial to anticancer effects. The introduction of a bromine atom at the 4-position enhances the electrophilicity of the molecule, facilitating further functionalization through cross-coupling reactions such as Suzuki-Miyaura, Heck, and Buchwald-Hartwig couplings. These reactions are pivotal in constructing complex molecular architectures, making 4-Bromo-1-methyl-1H-indazole a valuable building block in medicinal chemistry.

In recent years, there has been growing interest in indazole derivatives as potential therapeutic agents. One notable area of research involves their application in oncology. Studies have demonstrated that certain indazole compounds can modulate signaling pathways involved in tumor growth and metastasis. For instance, modifications at the 3-position of the indazole ring have been shown to enhance binding affinity to specific protein targets, leading to inhibitory effects on kinases and other enzymes implicated in cancer progression. The presence of both bromine and methyl groups in 4-Bromo-1-methyl-1H-indazole provides a strategic handle for further derivatization, allowing researchers to fine-tune its biological activity.

Another significant application of 4-Bromo-1-methyl-1H-indazole lies in its role as a precursor for synthesizing more complex heterocycles. The bromine atom serves as a reactive site for palladium-catalyzed reactions, enabling the construction of polycyclic systems with potential bioactivity. For example, recent publications have described the use of 4-Bromo-1-methyl-1H-indazole in generating fused indole-indazoles, which have shown promise in preclinical studies as inhibitors of bacterial enzymes. This highlights the compound's utility not only as an intermediate but also as a scaffold for designing novel antimicrobial agents.

The pharmaceutical industry has also explored 4-Bromo-1-methyl-1H-indazole for its potential in treating neurological disorders. Research indicates that indazole derivatives can interact with neurotransmitter receptors, offering insights into their role in modulating cognitive functions. The methyl group at the 1-position of 4-Bromo-1-methyl-1H-indazole contributes to its lipophilicity, which is often favorable for crossing the blood-brain barrier. This property makes it an attractive candidate for developing treatments targeting central nervous system disorders.

From a synthetic chemistry perspective, 4-Bromo-1-methyl-1H-indazole exemplifies the importance of functional group diversity in drug discovery. The combination of bromine and methyl substituents allows for multiple pathways to explore, including halogen exchange reactions and metal-catalyzed C-H activation. These strategies are increasingly employed to generate structurally diverse libraries of compounds for high-throughput screening. The versatility of 4-Bromo-1-methyl-1H-indazole underscores its significance as a reagent in modern synthetic methodologies.

In conclusion, 4-Bromo-1-methyl-1H-indazole (CAS No. 365427-30-1) is a multifaceted compound with broad applications in pharmaceutical research. Its unique structural features make it an invaluable intermediate for constructing biologically active molecules, particularly in oncology and antimicrobial therapy. As synthetic techniques continue to evolve, the potential uses of 4-Bromo-1-methyl-1H-indazole are expected to expand, further solidifying its role as a cornerstone in medicinal chemistry innovation.

• 465529-57-1(5-Bromo-1-methyl-1H-indazole)
• 1286734-86-8(6-Bromo-5-fluoro-1-methyl-1H-indazole)
• 1159511-77-9(4-Bromo-1,5-dimethyl-1H-indazole)
• 1000576-59-9(7-Bromo-1-methyl-1H-indazole)
• 590417-94-0(6-Bromo-1-methyl-1H-indazole)
• 701910-14-7(7-Bromo-2-methyl-2H-indazole)
• 465529-56-0(5-Bromo-2-methyl-2H-indazole)
• 590417-95-1(6-Bromo-2-methyl-2H-indazole)
• 590417-96-2(5-Bromo-1-ethylindazole)
• 590417-93-9(4-Bromo-2-methyl-2H-indazole)